Key points are not available for this paper at this time.
Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp VERTIS CV ClinicalTrials.gov number, NCT01986881.).
Cannon et al. (Wed,) studied this question.